Skip to Main Content

Sarepta Therapeutics became the toast of biotech on Tuesday after revealing early data on a gene therapy for Duchenne muscular dystrophy that far outstripped Wall Street’s expectations.

But Sarepta is hardly alone in the field, and nothing in biotech happens in a vacuum. Here’s a look at what the latest DMD results mean for the company’s competitors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.